Zheng-Wang Chen
Huazhong University of Science and Technology, China
Title: Aglycin and Vglycin, A New Generation peptide drug for treatment of T2D
Biography
Biography: Zheng-Wang Chen
Abstract
We have previously reported that the bioactive peptide aglycin regulates glucose homeostasis in type 2 diabetic (T2D) mice by the process of activating Insulin Receptor/Insulin Receptor Substrate1 Pathway (IR/IRS1 P). Furthermore, we have reported that the bioactive peptide vglycin, a homologous peptide of aglycin, normalizes fasting glucose and restores impaired pancreatic function in T2D Wistar rats. Both peptides aglycin and vglycin, consisted of 37 amino acid residues respectively and share 35 residues identically. In particular, the 6 cystines are located at the same sites and constitute the structure domain “cystine knot” which can resist hydrolysis from proteases in the digestive tract. Recently, we have successfully conducted the toxicity tests with the peptides, aglycin and vglycin, in rats and mice respectively. We have also determined their effectiveness in 107 volunteers with diabetes and prediabetes. Our findings reveal that the peptides aglycin or vglycin take a crucial role in the prevention and treatment of diabetes. We will report these results in the Diabetic Medications-2015 conference of USA.